Core Viewpoint - Exosomes, small vesicles released by living cells, are recognized as a promising area in biomedicine, with applications in disease diagnosis, cell therapy, drug delivery, and regenerative medicine. The regulatory inclusion of extracellular vesicles (EVs) as advanced therapy medicinal products (ATMPs) marks a significant step towards their industrial application, although challenges remain in technology, standards, and interdisciplinary collaboration [2]. Group 1: Exosome Overview - Exosomes are tiny vesicles with a diameter of 30-150 nm, serving as messengers for intercellular communication and signal transmission. They contain various bioactive substances, including proteins, functional DNA fragments, mRNAs, and miRNAs [2]. - The National Medical Products Administration (NMPA) in China has recognized EVs as part of the ATMP category, indicating a move towards regulatory standardization in the development of exosome-related products [2]. Group 2: Challenges in the Industry - The exosome industry faces three main challenges: the need for breakthroughs in key technologies, the establishment of industry standards, and the enhancement of interdisciplinary collaborative innovation [2]. Group 3: Upcoming Event - An online seminar titled "First Exosome Innovation Technology and Application Progress" will be held on August 12, 2025, organized by Instrument Information Network, focusing on advancements in exosome extraction, characterization, and applications in disease diagnosis and treatment [3][5]. - The seminar will feature various sessions, including topics on standardization, single-molecule characterization, clinical applications, and innovative detection methods related to exosomes [6].